Preclinical development of MK‐2214 a novel antibody targeting pS413 tau for the treatment of Alzheimer’s Disease
The preclinical profile presented here supports the clinical development of MK-2214 as an optimal tau antibody to slow the progression of AD.
Authors
- Oitak Wong
- Sean M. Smith (ORCID: https://orcid.org/0009-0008-3434-9397)
- Jonathan E. Kurz (ORCID: https://orcid.org/0000-0002-2259-4263)
- Michael Judo
- Sokreine Suon
- Jonathan A. Sugam
- Brad Smith
- Sophie Parmentier‐Batteur
- Rebecca M. Klein (ORCID: https://orcid.org/0000-0001-9638-3752)
- Jason M. Uslaner (ORCID: https://orcid.org/0000-0002-8952-5940)
- Jeanne Baker
- Seth Robey
- Xuemei Zhao
- Ying Chen
- Yuan Tian
- W. Joseph Herring
- Andrei Popescu
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- United States Military Academy (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_102913
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00